Poly(ADP-ribose) Polymerase Inhibitors

"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.

Descriptor ID	D000067856
MeSH Number(s)	D27.505.519.389.739 D27.505.954.248.692
Concept/Terms	Poly(ADP-ribose) Polymerase Inhibitors Poly(ADP-ribose) Polymerase Inhibitors Inhibitors of Poly(ADP-ribose) Polymerases Poly(ADP-ribosylation) Inhibitors PARP Inhibitors Inhibitors, PARP

Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Enzyme Inhibitors [D27.505.519.389]
Poly(ADP-ribose) Polymerase Inhibitors [D27.505.519.389.739]
Therapeutic Uses [D27.505.954]
Antineoplastic Agents [D27.505.954.248]
Poly(ADP-ribose) Polymerase Inhibitors [D27.505.954.248.692]

Below are MeSH descriptors whose meaning is related to "Poly(ADP-ribose) Polymerase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 12 publications over 9 distinct years, with a maximum of 3 publications in 2021

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2001	0	1	1
2013	0	1	1
2016	0	1	1
2019	0	1	1
2020	0	1	1
2021	2	1	3
2022	0	2	2
2024	1	0	1
2025	1	0	1

Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.

Whalen JM, Earley J, Wisniewski C, Mercurio AM, Cantor SB. Targeting BRCA1-deficient PARP inhibitor-resistant cells with nickases reveals nick resection as a cancer vulnerability. Nat Cancer. 2025 Feb; 6(2):278-291.

View in: PubMed
MacGilvary N, Cantor SB. Positioning loss of PARP1 activity as the central toxic event in BRCA-deficient cancer. DNA Repair (Amst). 2024 Dec; 144:103775.

View in: PubMed
Bhardwaj PV, Abdou YG. Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications. Curr Oncol Rep. 2022 12; 24(12):1791-1800.

View in: PubMed
Cong K, Cantor SB. Exploiting replication gaps for cancer therapy. Mol Cell. 2022 07 07; 82(13):2363-2369.

View in: PubMed
Rizzo A, Mollica V, Merler S, Morelli F, Sorgentoni G, Oderda M, Santoni M, Massari F. Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis. Expert Opin Drug Metab Toxicol. 2022 Mar; 18(3):235-240.

View in: PubMed
Paes Dias M, Tripathi V, van der Heijden I, Cong K, Manolika EM, Bhin J, Gogola E, Galanos P, Annunziato S, Lieftink C, And?jar-S?nchez M, Chakrabarty S, Smith GCM, van de Ven M, Beijersbergen RL, Bartkova J, Rottenberg S, Cantor S, Bartek J, Ray Chaudhuri A, Jonkers J. Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps. Mol Cell. 2021 11 18; 81(22):4692-4708.e9.

View in: PubMed
Cong K, Peng M, Kousholt AN, Lee WTC, Lee S, Nayak S, Krais J, VanderVere-Carozza PS, Pawelczak KS, Calvo J, Panzarino NJ, Turchi JJ, Johnson N, Jonkers J, Rothenberg E, Cantor SB. Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency. Mol Cell. 2021 08 05; 81(15):3128-3144.e7.

View in: PubMed
Tothova Z, Valton AL, Gorelov RA, Vallurupalli M, Krill-Burger JM, Holmes A, Landers CC, Haydu JE, Malolepsza E, Hartigan C, Donahue M, Popova KD, Koochaki S, Venev SV, Rivera J, Chen E, Lage K, Schenone M, D'Andrea AD, Carr SA, Morgan EA, Dekker J, Ebert BL. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML. JCI Insight. 2021 02 08; 6(3).

View in: PubMed
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.

View in: PubMed
Medina MA, Oza G, Sharma A, Arriaga LG, Hern?ndez Hern?ndez JM, Rotello VM, Ramirez JT. Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies. Int J Environ Res Public Health. 2020 03 20; 17(6).

View in: PubMed

People

Explore

Similar Concepts

Top Journals